| |
Placebo (n = 9)
|
Namilumab 150 mg (n = 8)
|
Namilumab 300 mg (n = 7)
|
Total (N = 24)
|
|---|
|
Gender, n (%)
|
|
Female
|
6 (67)
|
5 (63)
|
6 (86)
|
17 (71)
|
|
Male
|
3 (33)
|
3 (38)
|
1 (14)
|
7 (29)
|
|
Race, n (%)
|
|
White
|
9 (100)
|
7 (88)
|
7 (100)
|
23 (96)
|
|
Black
|
0
|
1 (13)
|
0
|
1 (4)
|
|
Age, yearsa
|
56 (29–65)
|
59 (43–65)
|
59 (36–75)
|
59 (29–75)
|
|
BMI, kg/m2b
|
27.37 (2.246)
|
24.69 (2.471)
|
28.30 (1.778)
|
26.75 (2.607)
|
|
Disease duration, years
|
3.3 (0.9–10.9)
|
4.9 (1.7–19.0)
|
5.2 (3.0–9.3)
|
4.4 (0.9–19.0)
|
|
DAS28-ESRb
|
4.8 (0.41)
|
4.9 (0.35)
|
4.4 (0.59)
|
4.7 (0.48)
|
|
DAS28-CRPb
|
4.4 (0.82)
|
4.2 (0.52)
|
4.0 (0.62)
|
4.2 (0.65)
|
|
ESR, mm/hourb
|
31 (11.91)
|
28 (5.56)
|
23 (8.06)
|
28 (9.31)
|
|
CRP, mg/literb
|
21 (22.64)
|
8 (6.75)
|
12 (10.44)
|
13 (15.43)
|
|
TJCb (0–68)
|
8.7 (5.45)
|
9.1 (6.92)
|
9.6 (4.69)
|
9.1 (5.55)
|
|
SJCb (0–66)
|
5.0 (5.41)
|
4.3 (2.38)
|
6.1 (5.30)
|
5.1 (4.45)
|
- The eligibility criteria allowed patients with previous biological therapy into the study, however, all of patients enrolled into the PRIORA study were biologic naive
-
BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SD standard deviation, SJC swollen joint count, TJC tender joint count
-
aMedian (range); bmean (SD)
